Occurrence of adverse events in patients with JIA receiving biologic agents: Long-term follow-up in a real-life setting

Rheumatology (United Kingdom)

Volumn 54, Issue 7, 2015, Pages 1170-1176

  Tarkiainen, Maarit ^a   Tynjälä, Pirjo ^a   Vähäsalo, Paula ^b,c,d   Lahdenne, Pekka ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b MEDICAL RESEARCH CENTER OULU   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF OULU   (Finland)

Author keywords

Adverse drug event; Anti rheumatic agent; Anti TNF; Biologic therapy; Disease modifying anti rheumatic drug; Juvenile idiopathic arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALANINE AMINOTRANSFERASE; BIOLOGICAL PRODUCT; CORTICOSTEROID; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADOLESCENT; ADRENAL CORTEX INSUFFICIENCY; ADULT; ADVERSE DRUG REACTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; APPENDICITIS; ARTICLE; ATYPICAL MYCOBACTERIOSIS; AUTOIMMUNE DISEASE; BACTERIAL PNEUMONIA; BIOLOGICAL THERAPY; BONE MARROW HYPOPLASIA; BONE NECROSIS; BRAIN CYST; BREAST CYST; BRONCHITIS; CATARACT; CHICKENPOX; CHILD; CONJUNCTIVITIS; CORTICOSTEROID THERAPY; COUGHING; CROHN DISEASE; DEPRESSION; DISEASE EXACERBATION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; ENCEPHALITIS; EPIDERMOID CYST; FATIGUE; FEMALE; FINLAND; FOLLOW UP; FURUNCULOSIS; GASTROENTERITIS; GLAUCOMA; HERPES ZOSTER; HUMAN; INFLUENZA; INFUSION RELATED REACTION; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; LICHEN PLANUS; MACROPHAGE ACTIVATION SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICAL TERMINOLOGY; MEDICATION COMPLIANCE; MENTAL DISEASE; MIGRAINE; MUSCLE DISEASE; MYALGIA; MYCOBACTERIUM AVIUM PNEUMONIA; NAUSEA; OBESITY; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; OSTEOPENIA; OSTEOPOROSIS; OTITIS MEDIA; PATIENT COMPLIANCE; PATIENT SAFETY; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PYELONEPHRITIS; PYREXIA IDIOPATHICA; RETROSPECTIVE STUDY; SCHOOL CHILD; SEPTICEMIA; SIDE EFFECT; SINUSITIS; SKIN INFECTION; SPLEEN CYST; STEVENS JOHNSON SYNDROME; STOMACH PAIN; TERTIARY HEALTH CARE; TONSILLITIS; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERINE CERVIX TUMOR; UVEITIS; VASCULITIS; VERRUCA VULGARIS; WEGENER GRANULOMATOSIS; WOUND INFECTION;

EID: 84936874929     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu457     Document Type: Article

References (14)

1. Berntson L, Andersson Gare B, Fasth A et al. Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol 2003;30: 2275-82.
2. Danner S, Sordet C, Terzic J et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol 2006; 33:1377-81.
3. Peterson LS, Mason T, Nelson AM, O'Fallon WM, Gabriel SE. Juvenile rheumatoid arthritis in Rochester, Minnesota 1960-1993 Is the epidemiology changing? Arthritis Rheum 1996;39:1385-90.
4. Lovell DJ, Reiff A, Ilowite NT et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504.
5. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62:245-7.
6. Ruperto N, Lovell DJ, Cuttica R et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010;69:718-22.
7. Lovell DJ, Ruperto N, Goodman S et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
8. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72:517-24.
9. Adverse Events (CTCAE) Version 4.0. http://evs.nci.nih. gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_Quick Reference:8.5x11.pdf (9 February 2013, date last accessed).
10. Otten MH, Prince FH, Anink J et al. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Ann Rheum Dis 2013;72: 721-7.
11. Horneff G, De Bock F, Foeldvari I et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25.
12. Giannini EH, Ilowite NT, Lovell DJ et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2794-804.
13. Tarkiainen M, Tynjala P, Vahasalo P, Lahdenne P. Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab. Scand J Rheumatol 2011;40:150-60.
14. Tynjala P, Vahasalo P, Tarkiainen M et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomized open-label clinical trial. Ann Rheum Dis 2011; 70:1605-12.